Discussion of Abivax Clinical Program involving Covid-19, Ulcerative Colitis, Crohn’s Disease and more
Hartmut Ehrlich and Philippe Pouletty discuss Abivax Pipeline of Clinical Programs involving Covid-19, Ulcerative Colitis, Crohn’s Disease and more.
Ongoing Phase 2b/3 trial with ABX464 in Covid-19 (miR-AGE trial), the unique properties of the lead candidate (antiviral, anti-inflammatory, tissue repair) to treat elderly and high-risk Covid-19 patients, the rial is ongoing in Europe and Brazil (Mexico, Peru and Chile to follow shortly)
ABX196 has been developed as a synthetic agonist of iNKT cells from a proprietary platform technology that identifies agonists of these types of cells that demonstrate immune enhancing effects in cancer models. Preclinical data showed that ABX196 enhanced anti-tumoral activity when used alone and in combination with anti-PD1 antibodies or doxorubicin
ABX464 in Inflammatory Bowel Diseases (Abivax development priority), excellent two-year efficacy and safety data for ABX464 ulcerative colitis Phase 2a maintenance study and ongoing ulcerative colitis Phase 2b trial in 15 countries, the US and Canada
Planned pivotal Phase 2b/3 trial with ABX464 in Crohn’s disease (FPI Q1 2021) and ngoing clinical trial with ABX464 in rheumatoid arthritis in 5 European countries
Ongoing clinical trial with second molecule, ABX196, in patients with hepatocellular carcinoma in the US
Also to be discovered
Centers for Medicare & Medicaid Services (CMS) grant transitional pass-through (TPT) payment for Stryker's SpineJack® System
CMS announced the SpineJack implantable fracture reduction system qualified for the TPT payment as part of the 2021 Medicare Payment System.
Great article about Abivax : what makes it a unique candidate to treat Covid-19
In addition to its exciting results in ulcerative colitis...